Gabriella Camboni
Partner
Works at Sofinnova
Investor profile | Builders Republic
About
Partner at Sofinnova, Gabriella Camboni invests from Pre-Seed to Series B and in Growth, with check sizes ranging from €1 to €60 million, particularly in agri-food, health and life sciences, and climate and cleantech. A Partner of the Biovelocita Strategy, she is co-founder and CEO of BiovelocITA. She also co-founded Ethical Oncology Science in 2006, which was sold to Clovis in 2013, and Novuspharma. Her track record includes BioClec, BiovelocITA, Ethical Oncology Science, and Novuspharma. MD from the University of Milan.
Profile
- Role
- Partner
- Fund
- Sofinnova